A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Italy- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Back to Italy804 clinical trials in Florence, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in ItalyStudi-Clinici.it(opens in a new tab)
Italy
Italy
Italy
Italy
Italy
Italy
Italy
Italy
Italy
Italy
Italy
ItalyThe busiest research cities in the country
What the registry says about research in the country
Clinical research focusing on innovative treatments for frontotemporal dementia, multiple sclerosis, and Dravet syndrome. Studies evaluate novel therapeutic approaches including DNL593 for FTD and frexalimab for relapsing MS.
Emphasis on safety assessment and long-term efficacy monitoring.
Comprehensive studies targeting various cancer types including colorectal cancer, breast cancer, and lung cancer. Trials explore combination therapies and novel treatment approaches.
Focus on targeted therapies and personalized treatment approaches.
Investigating treatments for psoriatic arthritis, Sjögren's syndrome, and systemic sclerosis. Research includes evaluation of new biologics and targeted therapies.
Studies aim to improve quality of life and disease management.
Studies examining treatments for COPD and respiratory infections, including evaluation of tezepelumab for moderate to severe COPD and prevention of RSV in infants.
Focus on improving respiratory outcomes and prevention strategies.
Tell us about your condition – we search every trial in Europe and connect you with the right site.